New study aims to personalize throat cancer treatment using genetic tests and MRI
NCT ID NCT07407205
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether genetic markers (like tumor mutations and DNA in the blood) and special MRI scans can predict how well chemoradiotherapy works for patients with HPV-negative oropharyngeal cancer. Researchers will follow 30 patients to see if these tests can forecast treatment response and disease progression. The goal is to tailor therapy and reduce the number of follow-up scans needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients will respond best to chemoradiotherapy, potentially personalizing treatment and reducing unnecessary scans.
- What could go wrong
- This is a small, early-stage study with only 30 participants, so results may not apply to everyone. The biomarkers being tested may not reliably predict outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-NEGATIVE OROPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less radiation be safer for throat cancer?
- Can a simple swab predict who needs less radiation?
- New drug combo aims to shrink oral cancers before surgery
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
- New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
- New pill-chemo combo takes on hard-to-treat cancers